Biomedical subjects

D Corapcioglu

Publications and source records attributed to D Corapcioglu.

4 recordsLinked to original sources

PubMed2004

I-131 therapy for thyroglobulin positive patients without anatomical evidence of persistent disease.

OBJECTIVE: the aim of this retrospective study was to evaluate the diagnostic relevance of I-131 whole body scan (WBS) performed after second empirical therapeutic doses of iodine-131 (I-131) in thyroglobulin (Tg)-positive thyroid cancer patients without evidence of local and distant metastasis. We also evaluated the efficacy of second empirical therapeutic doses of I-131 in these patients. METHODS: we retrospectively compared the results of diagnostic I-131 WBS and post-therapy scans of second therapeutic doses of I-131 in 38 patients with detectable Tg while off T4 therapy (TSH>25 mlU/ml). All patients underwent a near-total or total thyroidectomy and I-131 ablation with 75-125 mCi. All of the reported subjects had no prior evidence for detectable disease before second high dose empirical I-131 therapy. RESULTS: there was almost complete concordance in uptake between diagnostic I-131 WBS and final scans carried out after second I-131 therapy in 22 out of 38 patients. Whereas abnormal foci of new uptake was detected in all of the remaining 16 patients, seven of them were found to have negative diagnostic WBS results. Distant metastases were observed in 3 of 16 subjects and mediastinal uptake was found in 2 of 16 patients in post-therapy scan. During the subsequent follow-up, extending from 8-46 months, 6 out of 16 patients showed normalization of serum Tg levels while off T4. Serum Tg levels were normalized in 3 out of 7 patients who had negative WBS results, increased in one and unchanged in the remaining 3. None of the patients with distant metastases had normalization of Tg levels. Totally, 6 out of 38 showed normalization of Tg levels while off T4 therapy. CONCLUSION: the empirical therapeutic doses of 1-131 may help in localization of the disease in Tg positive patients without anatomical evidence of persistent disease, but the effect of I-131 therapy on long-term survival is not obvious.

Adult↗

PubMed2004

Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.

We aimed to investigate whether metformin would reverse the endocrinopathy of polycystic ovary syndrome (PCOS), allowing resumption of cyclic ovulation and regular menses, and whether metformin causes any change in the serum concentration of insulin-like growth factor-I (IGF-I) in patients with PCOS. Fifty-eight women with PCOS participated in the study and received metformin at a dose of 850 mg three times a day (total 2550 mg) for 16 weeks. Serum concentrations of luteinizing hormone, follicle stimulating hormone, estradiol, free testosterone, total testosterone, 17-hydroxyprogesterone, dehydroepiandrosterone sulfate, fasting insulin, IGF-I, sex hormone binding globulin and insulin-like growth factor binding protein-1 (IGFBP-1) were evaluated before and after metformin treatment. Patients were divided into two groups as responders and non-responders according to the achievement of regular menstrual periods. The mean IGF-I levels decreased significantly on metformin therapy. After 16 weeks of metformin treatment, 55.17% of PCOS patients achieved regular menses. Only the change in serum levels of progesterone and IGF-I on metformin were statistically significant between responders and non-responders; metformin-induced decremental change in IGF-I levels were greater in responders. In conclusion, we observed that elevated IGF-I levels may have a crucial role in many consequences of PCOS in addition to hyperinsulinemia. By decreasing insulin and IGF-I levels, metformin therapy offers additional beneficial effects in resumption of regular menses. Thus, in PCOS patients with elevated levels of IGF-I, metformin may be considered as an appropriate agent to be used for the regulation of menstrual cycles.

17-alpha-Hydroxyprogesterone↗

PubMed1995

Obesity and left ventricular diastolic dysfunction.

To assess the influence of obesity on left ventricular function, 20 obese women (mean body mass index (BMI) 33.8 +/- 3.1 kg/m2 and mean age 31.1 +/- 2.4 years) without evidence of heart disease were evaluated by echocardiography. Obese subjects had greater left ventricular mass index (103 +/- 22 g/m2, 76 +/- 18 g/m2; P < 0.0001) and augmented fractional shortening (39 +/- 2.6%, 36 +/- 0.1%; P < 0.0001) than normals. Isovolumic relaxation time was prolonged in the obese group (92 +/- 11 ms) as compared with the control group (76 +/- 11 ms; P < 0.0001). The ratio of peak early and atrial filling velocities was significantly lower (1.2 +/- 0.4, 1.9 +/- 0.6; P < 0.0001) and atrial contribution was higher (39 +/- 9, 25 +/- 5; P < 0.0001) in obese subjects than in normals. Shortened deceleration time was measured in obese subjects (142 +/- 30, 179 +/- 20 ms; P < 0.0001). In conclusion, obesity causes relaxation and early filling abnormalities and diastolic filling is compensated by augmented atrial contribution. Diastolic dysfunction is an early indicator of cardiac involvement in obesity.

Adult↗

PubMedDate not supplied

Plasma leptin concentrations in patients with Graves' disease with or without ophthalmopathy.

BACKGROUND: Recent studies have demonstrated that human preadipocyte fibroblasts in orbital connective tissues from patients with Graves' ophthalmopathy differentiate into cells resembling adipocytes and acquire expression of leptin and functional thyroid stimulating hormone receptors. These finding imply that leptin may play a role in the pathogenesis of Graves' ophthalmopathy. However, little is known about plasma leptin concentration in patients with Graves' disease with or without ophthalmopathy. MATERIAL AND METHODS: To investigate this relationship; 28 patients with active Graves' ophthalmopathy (19 female and 9 male, mean age: 32.7+/-10.5 years, mean BMI: 24.8+/-3.7 kg/m2) and 10 patients without ophthalmopathy (6 female and 4 male, mean age: 24.6+/-5.6, mean BMI: 23.02+/-2.4 kg/m2) all with untreated Graves' disease were included in the study at first diagnosis in our endocrinology out-patient clinic. Sex-, BMI- and age-matched twenty healthy subjects (13 female, 7 male, mean age: 31.9+/-10.0, mean BMI: 24.2+/-3.0 kg/m2) were selected as a control group. Plasma leptin levels were measured by a RIA method with a sensitivity of 0.5 ng/ml. RESULTS: Results showed any significant differences neither between patients and controls (7.97+/-5.2 ng/ml vs. 7.83+/-3.7 ng/ml) nor between patients with or without Graves' ophthalmopathy (8.29+/-5.0 ng/ml vs. 7.06+/-5.8 ng/ml) (both P>0.05). Moreover, no correlation was found between plasma leptin levels and ophthalmopathy index score, or proptosis. CONCLUSIONS: Although effects of local leptin production in the orbit cannot be excluded, our data suggest that circulating plasma leptin does not have a significant direct influence on ophthalmopathy index score or pathophysiology of Graves' ophthalmopathy.

Adult↗